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Pleural Disease
AbstrAct
Introduction Non-expansile lung (NEL) is a common 
cause of talc pleurodesis (TP) failure in malignant pleural 
effusion (MPE), but is often occult prior to drainage. 
Reliable detection of NEL would allow patients to be 
allocated between intrapleural catheter (IPC) and TP. High 
pleural elastance (PEL) has been associated with NEL in 
observational studies. Pre-EDIT is a randomised feasibility 
trial of elastance-directed IPC or TP (EDIT) management 
using a novel, purpose-built digital pleural manometer 
(Rocket Medical, UK).
Methods and analysis Consecutive patients with MPE 
without prior evidence of NEL or preference for IPC will be 
randomised 1:1 between EDIT management and standard 
care (an attempt at TP). The primary objective is to 
determine whether sufficient numbers of patients (defined 
as 30 within 12 months (or 15 over 6 months)) can be 
recruited and randomised to justify a subsequent phase III 
trial testing the efficacy of EDIT management. Secondary 
objectives include safety, technical feasibility and validation 
of study design elements, including the definition of PEL 
using 4D pleural MRI before and after fluid aspiration. EDIT 
involves PEL assessment during a large volume pleural fluid 
aspiration, followed by an attempt at TP or placement of 
an IPC within 24 hours. Patients will be allocated to IPC if 
the rolling average PEL sustained over at least 250 mL fluid 
aspirated (PEL250) is ≥ 14.5 cm H2O/L.
Ethics and dissemination Pre-EDIT was approved by 
the West of Scotland Regional Ethics Committee on 8 
March 2017 (Ref: 17/WS/0042). Results will be presented 
at scientific meetings and published in peer-reviewed 
journals.
trial registration number NCT03319186; Pre-results.
IntroductIon
Malignant pleural effusion (MPE) is a 
common clinical condition and frequently 
leads to disabling breathlessness. Survival in 
patients with MPE is notably heterogeneous 
and is determined primarily by tumour type. 
However, most patients survive for less than a 
year and in some, this may be limited to a few 
months.1 Efficient palliation of MPE symp-
toms is therefore a major priority for patients 
and their families. This is currently achieved 
either by admission to hospital for intercostal 
drain placement and an attempt at talc pleu-
rodesis (TP) or outpatient placement of an 
indwelling pleural catheter (IPC).2 When 
successful, TP results in durable symptom 
control after a 4–7 day hospital stay, and obvi-
ates the need for intermittent, domiciliary 
drainage and the risk of ongoing complica-
tions including pleural infection. However, 
non-expansile lung (NEL) frequently compli-
cates an attempt at TP and cannot be reliably 
predicted using baseline radiology or other 
parameters. Since an IPC will effectively 
palliate most MPEs, regardless of NEL,2 some 
centres advocate their use in all patients with 
MPE. However, an IPC is not acceptable to 
some patients. Anecdotally, this is particu-
larly the case if immunosuppressive cancer 
therapy is planned, or their lifestyle or envi-
ronment makes IPC management inconven-
ient or overly restrictive (eg, patients who 
enjoy swimming or reside in a warm climate).
Strengths and limitations of this study
 ► A  prospective assessment of the feasibility of a 
novel, pleural elastance (PEL)-directed treatment 
pathway (EDIT management) for malignant pleural 
effusion.
 ► It  utilises purpose-built digital pleural manometry 
equipment allowing continuous intrapleural pressure 
recording, and derivation of PEL via a user-friendly 
interface.
 ► It  includes pre-aspiration and post-aspiration 4D 
pleural MRI to validate assumptions regarding an-
atomical changes during fluid aspiration, the com-
putation of P
EL and the origin of symptoms, such as 
cough and chest pain.
 ► It is a single-centre feasibility study; not powered to 
evaluate the efficacy of EDIT management but will 
inform the design a larger future trial using a pa-
tient-centred primary outcome measure.
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Current guidelines direct clinicians to offer a choice 
between TP or IPC based on patient preference, given 
the equivalent efficacy of these approaches in two 
randomised controlled trials.3 However, this apparent 
equivalence cannot be generalised to patients with NEL, 
since the incidence of NEL was extremely low in these 
important studies, occurring in only 3/54 (6%) and 2/72 
(3%) patients in TIME-2 and AMPLE, respectively.4 5 In 
clinical practice, the incidence of NEL is almost certainly 
higher; in audit data recently reported by our unit, NEL 
was identified in 15/65 patients with MPE (23%) who 
underwent complete pleural fluid drainage.6 In this 
series, NEL was also associated with a twofold to fourfold 
increase in all-cause mortality, which may explain the 
under-representation of NEL in the TIME-2 and AMPLE 
studies.6
In our view, the ideal MPE treatment pathway would 
incorporate an initial functional assessment to determine 
the probability of underlying NEL, given the profound 
impact this has on the decision-making required by 
current guidelines (TP or IPC). Such a pathway, if accu-
rate and efficient, would maximise patient choice in 
those with expansile lung (who could reasonably choose 
between TP and IPC) and minimise the rate of futile TP 
attempts in patients with NEL (avoiding the associated 
risks, cost and inconvenience). The current randomised 
feasibility pre-EDIT trial has been initiated to assess the 
feasibility and inform the design of a future randomised 
phase III trial testing the efficacy of elastance-directed 
IPC or TP (EDIT) management. Pre-EDIT also includes a 
Treatment Preferences Survey (TPS) to more adequately 
record patient views regarding decision-making in MPE 
management.
rationale for the pre-EdIt trial
Detection of NEL
Using routinely available clinical information NEL cannot 
be reliably detected prior to complete pleural drainage. 
A thick visceral peel encasing the lung may be seen on 
cross-sectional imaging in gross cases but is frequently 
absent. Following diagnostic or therapeutic pleural fluid 
aspiration, an ex-vacuo (hydro-) pneumothorax may be 
visible.2 However, this is also an insensitive sign, since a 
NEL may re-expand enough to appear expansile after 
removal of currently recommended volumes of fluid 
(< 1.5 litres). Even after complete drainage of MPE, we 
have recently reported considerable interobserver vari-
ation in radiographic detection of NEL.6 Sonographic 
findings, including heavy septation or visceral pleural 
thickening,7 or abnormal M-mode and speckle-tracking 
end-points,8 have recently been reported as potential NEL 
biomarkers, but have yet to be validated in large cohorts. 
Development of a reliable predrainage biomarker for 
NEL is therefore urgently required.
Pleural elastance (PEL) is an intrinsic property of the 
pleural cavity and is defined following thoracentesis by 
the change in intrapleural pressure (∆IPP) divided by 
the change in pleural cavity volume, which is assumed 
to be equal to the volume of fluid removed (∆VOUT).
9 
In previous observational studies, elevated PEL has been 
strongly associated with the presence of NEL and the 
occurrence of TP failure.10 However, previous studies 
have not attempted to allocate patients to TP or IPC 
using PEL measurements. For this to be feasible, safe 
and reliable, various technical difficulties regarding IPP 
measurement need to addressed, in addition to pathway 
and trial design issues that are summarised below.
Technical considerations in IPP measurement
Previous pleural manometry equipment has been 
hampered by technical limitations, largely relating to 
poor damping of pressure variations related to normal 
respiration and/or the need for cumbersome impro-
vised equipment. In conjunction with Rocket Medical 
(UK), we have developed a novel, single-use, CE-marked 
digital pleural manometry (DPM) catheter which allows 
continuous IPP measurement during thoracentesis (see 
figure 1). IPP is measured once per second and is mechan-
ically damped via the narrow independent lumen linking 
the pleural cavity to the electronic transducer (ET). IPP 
is also temporally damped by displaying a mean IPP on 
a re-usable digital display unit, based on the preceding 
5 s of data. The precision and accuracy of the electronic 
transducer within the catheter has been laboratory tested 
by Rocket Medical (UK) during product development 
and found to read within ±5% of a calibrated labora-
tory device at simulated pressures between +20 and −30 
cmH2O. The manometer was EMC tested and passed BS 
EN 60601-1-2:2015 and BS EN 60601-1:2006+A1:2013.
EDIT pathway design
Monophasic vs biphasic NEL and selection of an abnormal PEL 
threshold
Previous studies have reported characteristic patterns 
of IPP change in patients with NEL and expansile lung, 
during thoracentesis.9 11 12 Expansile lung is typically 
associated with a small linear reduction in IPP over the 
course of a large volume pleural aspiration. In contrast, 
NEL results in much larger fall in IPP, reflecting high PEL. 
This may occur early in the procedure where the aggre-
gated compliance of the lung and parietal structures 
Figure 1 Rocket Medical (UK) digital pleural manometer 
and re-usable display unit.
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is severely limited resulting in a steep linear fall in IPP 
(monophasic NEL), typically in patients with gross 
visceral pleural thickening. In more subtle forms of NEL, 
IPP may initially behave similarly to expansile lung, as the 
pleural space partially conforms to the volume change 
and/or the lung expands as much as it can. However, 
this accommodation will eventually be overwhelmed as 
the lung reaches its maximum expansion, leading to a 
fall in IPP, but only after a considerable volume of fluid 
has been removed. This results in a biphasic PEL curve, 
which can only be detected if sufficient fluid is removed 
to reach the relevant inflection point. Importantly, TP 
success is likely to be reduced in patients with mono-
phasic and biphasic NEL, and the EDIT pathway needs 
to be capable of detecting both.
In the only previous study that has linked PEL to TP 
success, Lan et al demonstrated that a PEL threshold of ≥ 
19 cm H2O/L following aspiration of 500 mL of pleural 
fluid was associated with a sensitivity for NEL of 79% 
(95% CI 0.49 to 0.99).10 However, the sensitivity of this 
approach is likely to have been limited by selection of a PEL 
threshold significantly above the upper limit of normal, 
which was subsequently defined as 14.5 cm H2O/L,
13 and 
the small aspiration volume used (500 mL), which is likely 
to have been inadequate to detect all cases of biphasic 
NEL. Adopting a lower PEL threshold and using a larger 
total aspiration volume may increase the sensitivity of 
NEL detection, but could potentially sacrifice specificity, 
particularly if IPP rises transiently due to coughing or 
unknown measurement artefacts.
Therefore, in the current pre-EDIT trial, we will use 
a novel definition of NEL, based on a rolling average of 
PEL recording over the preceding 250 mL fluid removed 
(PEL250), during a large volume pleural aspiration. The 
aspiration volume will only be limited by symptoms, a 
drop in IPP below previously reported safety thresholds 
or a target pleural effusion depth, based on repeated 
sonographic measurements (see Methods and analysis 
section for further detail). IPP pressures used to derive 
PEL will be consistently measured at end-expiration. NEL 
will be defined by a maximum PEL250 ≥ 14.5 cm H2O/L 
(the previously reported upper limit of the normal range 
for PEL)
13 occurring at any point during large volume aspi-
ration. This definition aims to detect NEL at the earliest 
possible opportunity, including in patients with biphasic 
NEL, while preserving specificity.
Delivery of elastance-directed management and safety 
considerations
By definition, the EDIT pathway requires an additional 
large volume thoracentesis prior to allocation to TP 
or IPC. If the allocated procedure cannot be delivered 
promptly, ideally on the same day, this offsets any pathway 
efficiency gained through detection of NEL. However, 
placement of any form of Seldinger drain may be tech-
nically challenging after removal of the majority of the 
effusion during PEL assessment. Therefore, within the 
EDIT protocol, thoracic ultrasound (TUS) images will 
be acquired regularly during aspiration, and the proce-
dure terminated once a minimum safe depth of effusion 
has been reached (see Methods and analysis section for 
further details). The protocol also allows that, if required, 
a ‘Boutin-type’ needle can employed for pneumothorax 
induction to ensure safe placement of PEL-allocated IPC 
or TP. This is regularly practised at level II thoracoscopy 
centres, including our own, when no, or minimal, pleural 
fluid is present at local anaesthetic thoracoscopy.14 
However, if the current study finds that this is frequently 
required to deliver EDIT management, this may impact 
on the feasibility of subsequent multicentre phase III trial 
and any subsequent clinical deployment.
Validation of the current definition of PEL using volumetric MRI
PEL is currently defined as ∆IPP (cm H2O)/∆VOUT (L), 
based on the assumption that ∆VOUT is equivalent to the 
underlying change in pleural cavity volume. However, 
this assumption may not be valid, due to a combination 
of air and local anaesthetic introduced during the proce-
dure, variable compliance of the surrounding structures 
and transient parenchymal-pleural fistulation. More-
over, since ∆IPP describes the aggregated behaviour of a 
potentially biphasic process, PEL values may inadequately 
describe pleural physiology in this setting. This uncer-
tainty will be explored in the secondary objectives using 
volumetric pleural MRI, which allows precise measure-
ment of intrathoracic structures.15–17
If the current definition of PEL is validated using MRI, 
this may enhance the usability of the device used here. 
In the current protocol, ∆VOUT needs to be manually 
recorded in parallel with IPP and the data integrated 
post-procedure. In the future, real-time integration 
of validated ∆VOUT data with IPP data could facilitate 
real-time display of PEL (or PEL250), circumventing this 
time-consuming step. As exploratory objectives, volu-
metric MRI data will also be correlated with the devel-
opment of symptoms during thoracentesis, the origin of 
which are poorly understood.18
Treatment preferences survey
All potentially eligible (pre-screened) patients will be 
asked to complete a TPS (see online supplementary 
appendix 1). These qualitative data will be of value 
in deciding whether to pursue future studies of EDIT 
management and optimising the design of these.
MEthods And AnAlysIs
study design and setting
Pre-EDIT is a randomised feasibility trial. Thirty patients 
with symptomatic MPE will be recruited at a single 
centre: The Queen Elizabeth University Hospital, 
Glasgow, UK. Potentially eligible patients will also be 
identified and pre-screened at Glasgow Royal Infirmary. 
Patients will be randomised 1:1 to receive either pleural 
elastance-directed IPC or TP (‘EDIT management’), or 
standard care (placement of an intercostal drain and 
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attempt at TP). A TPS will be offered to all potentially 
eligible (pre-screened) patients. The trial is sponsored by 
National Health Service (NHS) Greater Glasgow & Clyde 
and jointly funded by Rocket Medical (UK) and The West 
of Scotland Lung Cancer Research Group. The overall 
trial design is summarised in figure 2.
sample size
As a feasibility study, this trial is not subject to a formal 
sample size estimation. Recruitment of 30 patients is likely 
to allow a reasonable view of the barriers which might be 
met in delivering EDIT management, to explore possible 
solutions, to document the time required to deliver the 
Figure 2 Pre-EDIT trial flow chart. EDIT, elastance-directed intrapleural catheter or talc pleurodesis; IPC, intrapleural 
catheter; IPP, intrapleural pressure; MPE, malignant pleural effusion; NEL, non-expansile lung; PEL, pleural elastance; TP, talc 
pleurodesis; TUS, thoracic ultrasound; ∆VOUT, volume of fluid removed. 
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procedure and to refine training. Previous estimates 
of NEL incidence indicate that each arm of the study 
is likely to contain only a small number of NEL cases 
which will clearly limit the conclusions that can be drawn 
regarding the chosen PEL250 threshold and MRI data. 
These have therefore been set as unpowered secondary 
and exploratory objectives. Instead, a particular focus will 
be the impact of the study design on recruitment rate, 
including the requirement for two pleural procedures 
and randomisation between two treatment arms. This 
will be assessed by careful review of (pre-) screening logs 
for consistent reasons for screen failure or unwillingness 
to participate.
Since pre-EDIT involves novel equipment and imaging 
protocols, a review of data completeness and quality will 
be undertaken after completion of TUS assessment, DPM 
and MRI scanning in the first five patients randomised to 
EDIT management. This initial experience may be used 
to refine trial-specific instructions (TSIs) for use in subse-
quent patients. If significant data are missing or data 
are of such poor quality as to be uninterpretable from 
these patients, recruitment may be extended by up to five 
patients to replace these.
study objectives and outcome measures
Primary objective
The primary objective is to determine whether it is 
possible to recruit and randomise 30 patients over 12 
months (or 15 patients in any 6-month period). The 
primary outcome measure will be recruitment rate.
Secondary and exploratory objectives
Secondary objectives and their associated outcome meas-
ures are summarised in table 1. Exploratory objectives are 
described in box 1.
screening and eligibility assessment
Potentially eligible patients (defined as patients with 
symptomatic MPE) will be pre-screened by members of 
the parent clinical teams via cancer multidisciplinary 
team meetings, routine outpatient appointments and 
during inpatient reviews. Consecutive pre-screened 
patients meeting all inclusion criteria and without assess-
able exclusion criteria will be included in a pre-screening 
log, provided with a patient information sheet (PIS) at 
the earliest possible opportunity (see online supplemen-
tary appendix 2) and invited to a formal screening visit, 
during which all eligibility criteria will be assessed (see 
below). These patients will be given at least 24 hours 
between provision of the PIS and consent to consider 
participation.
Inclusion criteria
1. Clinically confident diagnosis of MPE, defined as any 
of the following:
a. Pleural effusion with histocytologically proven pleu-
ral malignancy OR
b. Pleural effusion in the context of histocytologically 
proven malignancy elsewhere, without a clear alter-
native cause for fluid OR
Table 1 Secondary objectives and associated end points in the pre-EDIT study
Secondary objectives Secondary end points
To determine the feasibility of PEL computation using the novel DPM The time taken to perform the EDIT large volume aspiration, 
including measurement of ∆IPP using the DPM, recording of ∆V and 
computation of PEL
The failure rate of the procedure, defined as the proportion of patients 
in whom PEL cannot be computed
To determine the safety and tolerability of PEL computation using the 
novel DPM
The occurrence of chest pain, cough or breathlessness during the 
procedure
AEs) and SAEs associated with use of the DPM
To assess the pleural fluid aspiration volume required to detect 
abnormal PEL (where present)
The pleural fluid aspiration volume at which the rolling average pleural 
elastance over the preceding 250 mL (PEL250) first exceeds the upper 
limit of normal (14.5 cm H2O/L)
To determine the proportion of patients allocated to EDIT management 
who require pneumothorax induction to facilitate safe ICD/IPC 
insertion following DPM
The proportion of patients in whom pneumothorax induction is 
required to facilitate safe ICD/IPC insertion in the EDIT arm
To test the assumption that pleural cavity ∆V is equivalent to the 
volume of pleural fluid removed during aspiration
Pleural fluid aspiration volume (∆VOUT)
Pleural cavity volume change, as measured directly using volumetric 
MRI (∆VMRI; defined as pre-aspiration minus post-aspiration pleural 
cavity volume)
To test the accuracy of a predictive model of pleural effusion volume 
(VTUS) based on TUS measurements, which is a proposed inclusion 
criterion for the EDIT study
TUS estimated total pleural effusion volume (VTUS)
Pre-pleural fluid aspiration pleural cavity volume (VMRI)
AE, adverse events; DPM, digital pleural manometer; EDIT, elastance-direct intrapleural catheter or talc pleurodesis; ICD, intercostal drain; 
IPC, indwelling pleural catheter; IPP, intrapleural pressure; PEL, pleural elastance; SAE, serious adverse event; TUS, thoracic ultrasound; V, 
pleural fluid volume.
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c. Pleural effusion with typical features of malignancy 
with pleural involvement on cross-sectional imaging
2. Degree of breathlessness for which therapeutic pleu-
ral intervention would be offered.
3. Age > 18 years.
4. Expected survival > 3 months.
5. Written informed consent.
Exclusion criteria
1. Women who are pregnant or lactating.
2. Clinical suspicion of NEL for which TP would not be 
offered.
3. Patient preference for first-line IPC insertion.
4. Previous ipsilateral failed TP.
5. Estimated pleural fluid volume ≤ 1 L (defined by TUS).
6. Any contraindication to ICD or IPC insertion, includ-
ing:
a. Irreversible coagulopathy.
b. Inaccessible pleural collection, including lack of 
suitable IPC tunnel site.
7. Any contraindication to MRI scanning, including:
a. Claustrophobia.
b. Cardiac pacemaker.
c. Ferrous metal implants or retained ferrous metal 
foreign body.
d. Previously documented reaction to Gadolini-
um-containing intravenous contrast agent.
e. Significant renal impairment (estimated glomeru-
lar filtration rate < 30 mL/min).
Informed consent
Consent will be a two-step process. Pre-screened patients, 
potentially agreeable to trial involvement will be invited 
to a formal screening visit, during which a member of 
the research team will discuss the trial and seek written 
consent to formal screening (see online supplementary 
appendix 2). This will involve formal assessment of all 
eligibility criteria, including a bedside TUS for meas-
urement of pleural effusion volume (VTUS). Patients 
attending a screening visit will be added to a screening 
log. Patients meeting all eligibility criteria will be asked 
to give written consent to trial enrolment and randomi-
sation.
treatment preferences survey
All pre-screened patients will be eligible and asked to 
participate in the TPS, irrespective of whether they meet 
all eligibility criteria and/or wish to participate in the 
main trial. Pre-screened patients will be provided with a 
separate TPS PIS (see online supplementary appendix 
3) and will be given sufficient time, based on their own 
judgement, to consider participation before signing 
a separate consent form for involvement in the TPS 
(see online supplementary appendix 3).
trial interventions
The trial interventions are summarised in figure 2 and 
described in detail below. Further information, in the 
form of TSIs for all interventions are available in online 
supplementary appendices 4–9.
Baseline assessments
Following consent, elective hospital admission and base-
line assessment will be completed by a member of the 
trial team. The following data will be recorded prior to 
randomisation:
1. Patient demographics and physical characteristics.
2. Mode of presentation, current diagnosis and smoking 
history.
3. Eastern Cooperative Oncology Group performance 
status.
4. Medical history and current medication.
5. Previous pleural interventions.
6. Symptoms, including pain and breathlessness accord-
ing to 100 mm visual assessment (VA) scores.
7. Results of routine haematological and biochemical 
tests (within 10 days).
8. Baseline TUS findings.
Randomisation
Immediately after baseline assessment, patients will be 
randomised 1:1 and allocated using random permuted 
blocks to either EDIT management or standard care. A 
validated online system will be used (www. sealedenvelope. 
com). The availability of potential minimisation factors 
for the subsequent phase III EDIT trial will be recorded 
but not used in randomisation, including the LENT 
prognostic score.1 The allocated management strategy 
will commence within 72 hours of randomisation.
Standard care
Following procedure-specific written consent, a 12Fr 
intercostal drain will be placed to facilitate passive fluid 
drainage at a rate not exceeding 1000 mL/hour. Chest 
box 1 Exploratory objectives in the pre-EDIT study
 ► To explore anatomical changes using MRI that may account for the 
development of symptoms such as chest pain or cough during large 
volume thoracentesis.
 ► To explore the factors important to patients with symptomatic 
malignant pleural effusion when deciding upon first-line definitive 
pleural intervention.
 ► To develop a novel predictive model for pleural effusion volume 
estimation applicable to a wide range of effusion volumes using 
uniplanar TUS measurement.
 ► To evaluate the feasibility and potential utility of M-mode assess-
ment of cardiac impulse lung displacement in patients undergoing 
EDIT management.
 ► To investigate potential novel MRI biomarkers, such as viscer-
al pleural thickness and parenchymal volume change and strain 
during respiratory cycle pre-DPM, which may predict NEL.
DPM, digital pleural manometer; EDIT, elastance-direct intrapleural 
catheter or talc pleurodesis; NEL, non-expansile lung; TUS, thoracic 
ultrasound. 
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radiographs (CXRs) will be performed post-ICD inser-
tion and repeated every 18–24 hours following insertion. 
Four grams of sterile talc will be administered as a slurry, 
if there is no evidence of NEL or significant residual 
pleural fluid, as per existing guidelines.2 The intercostal 
drain will be removed once fluid output falls below 
250 mL in the preceding 24-hour period, in the presence 
of a patent drain.
Where NEL or residual fluid is identified, drain 
patency will be assessed by flushing. Thoracic suction 
may be applied at the discretion of the primary physi-
cian. An additional CXR will be repeated after a further 
18–24 hour period. Talc slurry will be administered once 
at least 50% re-apposition of the visceral and parietal 
pleural is achieved, based on visual CXR estimation, as 
per existing guidelines.2 If this is not achieved within 
48 hours of drain placement, further management will be 
at the discretion of the primary physician. Further details 
are given in online supplementary appendix 4.
EDIT management
MRI scanning prior to large volume pleural fluid aspiration and PEL 
assessment
Patients will be scanned using a 3.0T Siemens Prisma 
MRI scanner. The affected thoracic cavity will be local-
ised and an isotropic T1-weighted volume acquired 
using volumetric interpolated breath-hold examination 
(VIBE) sequences. A stack of axial slices covering the 
entire lung and surrounding pleura will be acquired as a 
set of short breath-holds. Time-resolved 3D MR imaging 
of the complete thorax will then be obtained during 
tidal free-breathing and maximal inspiratory/expira-
tory efforts. A modified time-resolved angiography with 
interleaved stochastic trajectories (TWIST) sequence 
will be used for this purpose. Following this, Gd-DTPA 
contrast (Gadovist) will be administered as a 15–40 mL 
bolus (0.05 mmol/kg). VIBE sequences will be reac-
quired at copied slice positions to provide comparative 
postcontrast images at multiple time points.19 Further 
scanning details are given in online supplementary 
appendix 5.
Thoracic ultrasound
Following MRI scanning, a TUS scan will be performed. 
This will allow the operator to identify a safe site for inser-
tion of the digital pleural manometry catheter, where 
possible, in the posterior axillary line in the second rib 
space above the costophrenic angle. Deviation from this 
site will be recorded. For assessment of the secondary 
objectives, measurement of the lateral, posterior and 
median subpulmonic effusion heights in centimetres 
(LH, PH and SH) will be performed with the patient 
sitting upright at 90°. The total pleural effusion volume 
(in millilitres) will be estimated using the Goecke formula 
(VTUS = (LH +SH) x 70).
20 For examination of the explor-
atory objectives (see box 1), M-mode measurements of 
the atelectatic lower lobe will also be acquired, during a 
breath hold at end-expiration.
Large volume pleural fluid aspiration and computation of PEL 
(PEL250)
After infiltration of the insertion site with local anaes-
thetic, the digital pleural aspiration catheter will be 
inserted at the site marked using TUS. Pleural fluid will 
be removed in 50 mL aliquots until any of the following 
occur:
 ► The patient develops chest discomfort or excessive 
coughing.
 ► An intrapleural pressure of ≤ −20 cmH2O is reached.
 ► The target maximum aspiration volume is reached 
(horizontal costal to visceral pleural distance ≤ 
30 mm).
Sequential end expiratory IPP measurements will be 
recorded after each 50 mL aliquot. Additionally, the 
highest and lowest IPP values recorded during maximal 
respiratory manoeuvres at 200, 500 and 1000 mL will be 
recorded. Postprocedure, PEL250 values will be calculated 
summarising PEL over the preceding 250 mL of fluid 
removed. The first PEL250 value will therefore be computed 
based on the IPP change between 0 and 250 mL divided 
by 0.25. Equivalent PEL250 values will then be computed 
after each subsequent 50 mL fluid removed. Thus, after 
300 mL has been removed, the next PEL250 value will be 
computed using the IPP change between 50 and 300 mL, 
again divided by 0.25. The highest recorded PEL250 in each 
case (MaxPEL250) and total pleural fluid volume removed 
will be recorded. Further details are given in online 
supplementary appendix 6.
MRI scanning after large volume pleural fluid aspiration and PEL 
assessment
Following DPM, a further thoracic MRI scan will be 
performed. Identical T1-weighted VIBE and TWIST 
sequences will be acquired; however, further intravenous 
contrast will not be administered.
Allocation and delivery of PEL-directed management
Participants will be allocated to IPC or an ICD and 
attempt at TP based on their highest recorded PEL250 in 
each case (MaxPEL250), as follows:
MaxPEL250 ≥ 14.5 cm H2O/L: allocated to IPC
MaxPEL250 < 14.5 cm H2O/L: allocated to ICD and an 
attempt at TP
The allocated procedure must be completed within 
24 hours of large volume pleural fluid aspiration and 
computation of PEL. Both will be performed using stan-
dard Seldinger techniques based on repeat TUS assess-
ment, unless there is insufficient residual fluid left for 
this purpose (in the judgement of the operator). In this 
situation, a ‘Boutin-type’ needle may be used to obtain 
blunt access to the pleural cavity and create an iatro-
genic (hydro-) pneumothorax for the purpose of safe 
drain insertion. The remainder of the ICD/IPC inser-
tion will then proceed in the usual fashion. A CXR will 
be performed postprocedure to assess the drain posi-
tion. Further detail is provided in online supplementary 
appendices 7–9.
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Management following PEL-directed IPC or intercostal drain 
insertion
Patients allocated to IPC placement will be managed 
using standard local policies, as detailed in the TSI (see 
online supplementary appendix 9). For patients allo-
cated to intercostal drain insertion and TP, postinser-
tion management will be identical to patients receiving 
standard care.
data collection and study visits
VA scores
VA scores for chest pain and breathlessness will be docu-
mented at baseline and then daily for 7 days following 
ICD or IPC placement. Following this, VA scores will 
be performed weekly until the 28-day clinical follow-up 
appointment.
Study follow-up visits
Routine clinical appointments are planned for all 
patients at approximately 7, 28, 60 and 90 days after 
discharge. A single-study-specific follow-up visit at 90 days 
(±10) will coincide with routine follow-up where possible. 
At this visit, a CXR will be acquired and details of hospital 
admissions, repeat pleural interventions, clinic visits and 
survival status shall be recorded based on clinical history, 
augmented by electronic records systems. Where patients 
are unfit or unable to attend clinic, or have died, these 
data shall be recorded using electronic systems.
Further pleural intervention
In the event of hospital readmission, further pleural 
procedures will not be restricted by study participation. 
Where a gradual return of breathlessness is encountered 
during follow-up, the research team will assess the likely 
cause. IPC complications such as infection or blockage 
will be managed at the discretion of the primary physician. 
If recurrent MPE is identified following TP and occupies 
greater than an estimated one-third of the hemithorax 
on CXR, IPC insertion or therapeutic pleural aspiration 
will be offered if clinically appropriate. Intervention for 
smaller volume MPE recurrence will be offered where 
treatment consensus is achieved with a second respira-
tory physician blinded to trial group allocation. In the 
event of disagreement, a third (blinded) casting opinion 
will be sought.
Data management
Study data will be recorded on paper case report forms 
and securely transferred to the Queen Elizabeth Univer-
sity Hospital Clinical Research Facility and entered into 
a trial database. All CXR, CT and MRI images relating to 
trial participation will be securely stored on NHS systems 
in line with routine clinical practice. Representative 
TUS images and M-mode cine clips will be stored on an 
encrypted trial hard drive.
statistical analysis plan
The primary objective of trial recruitment will be 
expressed as a mean monthly rate over the complete trial 
period and over each 6-month period during which the 
trial is open. The time taken to perform digital pleural 
manometry, its failure rate, the incidence of adverse 
events (AEs) and serious adverse events (SAEs) associ-
ated with EDIT management, the number of patients 
requiring a Boutin needle for ICD/IPC insertion and 
aspiration volume required to detect abnormal PEL will 
be reported by simple descriptive statistics or proportions 
where appropriate. Differences in mean/median values 
will be assessed using Students t-test or Wilcoxon rank 
test. Pearson χ2 test and exact 95% CIs will be used to 
compare proportions. A standard significance level of 
0.05 will be used. The Bland-Altman method will be used 
to assess agreement between ΔVOUT and ΔVMRI measure-
ments and between preaspiration VTUS and VMRI measure-
ments.
End of trial
Trial recruitment commenced on 28 August 2017 and 
will terminate on 28 August 2018 or after 30 patients 
have been recruited, whichever is soonest. Trial partic-
ipation will cease once the final patient has completed 
their 90-day follow-up.
changes to the study protocol since trial opening
The protocol described accurately reflects V.2.5 of the 
protocol, dated 15 December 2017. The protocol history 
is summarised below:
V.2.0, dated 4 March 2017
 ► At request of REC, recruitment process modified 
such that follow-up contact to invite for screening 
visit to be made by clinical nurse specialist rather than 
research team.
V.2.1, dated 5 April 2017
 ► References to ‘Boutin needle’ changed to ‘Boutin-
type needle’.
 ► Randomisation process changed from minimisation 
using LENT score to simple random 1:1 allocation 
with recording of availability of LENT score to assess 
feasibility of minimisation by LENT in future EDIT 
trial.
V.2.2, dated 11 May 2017
 ► Introduction of 5-patient ‘run-in’ period to allow 
refinement of TUS, DPM and MRI protocols and 
assessment of data completeness.
 ► Removal of statement committing to guidewire place-
ment down Boutin-type needle (where used).
 ► Removal of statement committing to pneumothorax 
induction in endoscopy suite.
V.2.3, dated 4 August 2017
 ► Extension of time allowed between randomisation 
and delivery of intervention from immediate to up 
to 72 hours.
V.2.4, dated 9 October 2017
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 ► Remove preprocedure TUS-estimated target volume 
as stop criterion for DPM and replace this with 
target horizontal costal-visceral pleural distance on 
TUS assessment at intervals during the aspiration 
procedure.
 ► Removal of 2-week follow-up appointment.
 ► Follow-up interval to start from date of discharge 
rather than date of procedure.
V.2.5, dated 15 December 2017
 ► Recording of pre-screened patients.
 ► Introduction of TPS.
EthIcs And dIssEMInAtIon
safety reporting
Details of any AEs or SAEs will be collected during 
routine and trial follow-up visits. All AEs and SAEs will be 
recorded in the patient’s medical records and reported 
to the trial sponsor.
dissemination
Pre-EDIT, and the ultimate intention to definitively eval-
uate EDIT management if found to feasible, will be publi-
cised at regional and national meetings. The results of 
pre-EDIT trial will be presented at scientific meetings 
and published in peer-reviewed journals.
trial management
A Trial Management Group consisting of the chief inves-
tigator, clinical research fellow, lead trial research nurse, 
statistician and administrative assistant will oversee the 
running of the trial and meet on a monthly basis.
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